John M. McLaughlin, PhD
Vice President and Global Medical Lead for Antifectives and COVID-19, Influenza, and mRNA vaccines at Pfizer.
Articles
Evaluating the Efficacy of Paxlovid in High-Risk Patients with Pre-Existing Immunity
October 22nd 2024John McLaughlin, PhD, examines high-risk individuals with prior SARS-CoV-2 immunity and presents that Paxlovid reduces the risk of hospitalization, death, and severe symptoms, highlighting its ongoing value for high-risk patients in a post-peak pandemic landscape.
Read More
Latest Updated Articles
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: March 9th 2022 | Updated: December 21st 2024
Effects of Switching Antibiotics Mid-Treatment on Antimicrobial Resistance
Published: December 5th 2024 | Updated: December 21st 2024
COVID-19 Therapy Roundtable: What is the Virus Today, Treatment Options, and Addressing the Pediatric Population
Published: December 19th 2024 | Updated: December 21st 2024
COVID-19 Roundtable: Should Clinicians Consider Off Label COVID Therapies?
Published: December 17th 2024 | Updated: December 21st 2024
Peer-Assisted Telemedicine Enables More People With Hepatitis C to Get into the Continuum of Care
Published: December 18th 2024 | Updated: December 21st 2024
Ethical and Innovative Use of AI in Infectious Disease
